JP7574222B2 - ピーナツアレルギー患者の生活の質を改善するための方法 - Google Patents

ピーナツアレルギー患者の生活の質を改善するための方法 Download PDF

Info

Publication number
JP7574222B2
JP7574222B2 JP2021566106A JP2021566106A JP7574222B2 JP 7574222 B2 JP7574222 B2 JP 7574222B2 JP 2021566106 A JP2021566106 A JP 2021566106A JP 2021566106 A JP2021566106 A JP 2021566106A JP 7574222 B2 JP7574222 B2 JP 7574222B2
Authority
JP
Japan
Prior art keywords
peanut
oral immunotherapy
period
patient
life
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021566106A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022532547A5 (cg-RX-API-DMAC7.html
JP2022532547A (ja
Inventor
クリスティーン バーチウッド,
Original Assignee
ソシエテ・デ・プロデュイ・ネスレ・エス・アー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソシエテ・デ・プロデュイ・ネスレ・エス・アー filed Critical ソシエテ・デ・プロデュイ・ネスレ・エス・アー
Publication of JP2022532547A publication Critical patent/JP2022532547A/ja
Publication of JP2022532547A5 publication Critical patent/JP2022532547A5/ja
Application granted granted Critical
Publication of JP7574222B2 publication Critical patent/JP7574222B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2021566106A 2019-05-10 2020-05-08 ピーナツアレルギー患者の生活の質を改善するための方法 Active JP7574222B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962846481P 2019-05-10 2019-05-10
US62/846,481 2019-05-10
US201962855384P 2019-05-31 2019-05-31
US62/855,384 2019-05-31
US202062967948P 2020-01-30 2020-01-30
US62/967,948 2020-01-30
PCT/US2020/032179 WO2020231843A1 (en) 2019-05-10 2020-05-08 Methods for improving the quality of life of a patient with a peanut allergy

Publications (3)

Publication Number Publication Date
JP2022532547A JP2022532547A (ja) 2022-07-15
JP2022532547A5 JP2022532547A5 (cg-RX-API-DMAC7.html) 2023-05-11
JP7574222B2 true JP7574222B2 (ja) 2024-10-28

Family

ID=73289227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021566106A Active JP7574222B2 (ja) 2019-05-10 2020-05-08 ピーナツアレルギー患者の生活の質を改善するための方法

Country Status (7)

Country Link
US (2) US11229673B2 (cg-RX-API-DMAC7.html)
EP (1) EP3965815A4 (cg-RX-API-DMAC7.html)
JP (1) JP7574222B2 (cg-RX-API-DMAC7.html)
CN (1) CN113966229A (cg-RX-API-DMAC7.html)
AU (1) AU2020276213A1 (cg-RX-API-DMAC7.html)
CA (1) CA3137295A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020231843A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
US12433945B2 (en) 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
CA3123605A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
JP7756664B2 (ja) 2020-07-01 2025-10-20 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 経口免疫療法のための医療スタッフ配置の決定
KR20230148769A (ko) 2022-04-15 2023-10-25 사회복지법인 삼성생명공익재단 경구면역요법을 이용한 식품알레르기 치료서비스 제공방법, 이를 구현하기 위한 기록매체에 저장된 컴퓨터 프로그램 및 시스템

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509606A (ja) 2011-03-17 2014-04-21 ケンブリッジ エンタープライズ リミティッド ピーナッツアレルギーの治療
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
WO2019089978A1 (en) 2017-11-02 2019-05-09 Aimmune Therapeutics, Inc. Methods of oral immunotherapy

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3809767A (en) 1969-05-12 1974-05-07 Griffith Laboratories Methods of making vegetable protein concentrates
AU1589492A (en) 1991-03-01 1992-10-06 Warner-Lambert Company Starch-based controlled release compositions
US20120164306A1 (en) 1993-08-03 2012-06-28 Girsh Leonard S Process for preparing hypoallergenic and reduced fat foods
JP3445593B2 (ja) 1994-09-10 2003-09-08 株式会社林原生物化学研究所 ペプチドとその用途
US20020018778A1 (en) 1999-12-06 2002-02-14 Caplan Michael J. Passive desensitization
EP1272213B1 (en) 2000-04-06 2006-03-08 SEER Pharmaceuticals, LLC. Microbial delivery system
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
CA2516291C (en) 2003-02-28 2012-02-14 Alk-Abello A/S Dosage form having a saccharide matrix
EP2545931A1 (en) 2004-03-19 2013-01-16 Herbs Spring, LLC Herbal therapy for the treatment of food allergy
ATE524561T1 (de) 2004-04-06 2011-09-15 Sinai School Medicine Verfahren zur bestimmung einer allergenreaktion unter verwendung von mikroarray-immunoassay- techniken
WO2007075171A1 (en) 2005-12-28 2007-07-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of fenofibrate having improved bioavailability
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
BRPI0920465A2 (pt) 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
CN102215825A (zh) 2008-11-19 2011-10-12 安万托特性材料股份有限公司 可直接压制的颗粒状的基于微晶纤维素的赋形剂、其制备方法及应用
WO2010069595A1 (en) 2008-12-19 2010-06-24 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
EP2364690A1 (en) 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
JP5800527B2 (ja) 2010-03-30 2015-10-28 日東電工株式会社 安定化医薬組成物、安定化医薬組成物溶液製剤、フィルム状製剤及びフィルム状製剤の製造方法
AR081776A1 (es) 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
EP2750705B1 (en) 2011-08-31 2022-11-16 Perosphere Technologies Inc. Methods for effectively and rapidly desensitizing allergic patients
WO2013087119A1 (en) 2011-12-16 2013-06-20 Hal Allergy Holding B.V. Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
PL2802333T3 (pl) 2012-01-13 2020-09-07 Chr. Hansen A/S Lactobacillus rhamnosus i Bifidobacterium animalis subsp. lactis do stosowania dla zapobiegania lub leczenia zakażeń górnych dróg oddechowych
MX2015010315A (es) 2013-03-14 2016-04-13 Aimmune Therapeutics Inc Fabricacion de formulaciones de mani para desensibilizacion oral.
CA2907915C (en) 2013-04-03 2023-03-07 Allertein Therapeutics, Llc Immunomodulatory nanoparticle compositions comprising a plurality of nanoparticles comprising biodegradable or biocompatible polymers and hydrophilic and hydrophobic cellular components
US9456628B2 (en) 2013-06-13 2016-10-04 D&E Gillespie Enterpries LLC Methods and products to provide oral nutritional care to subjects with dementia
US20150343075A1 (en) 2014-06-02 2015-12-03 Aimmune Therapeutics Placebo formulations and uses thereof
JP6910946B2 (ja) 2014-08-25 2021-07-28 アイミューン セラピューティクス,インコーポレイテッド タマゴのタンパク質製剤およびその製造方法
KR102234319B1 (ko) 2014-09-04 2021-04-01 헬신 헬쓰케어 에스.에이. 아나모렐린 기반의 의학적 치료
AU2015315628A1 (en) 2014-09-08 2017-04-20 Cephalon, Inc. Use of reslizumab to treat moderate to severe eosinophilic asthma
CN110381749A (zh) 2017-01-13 2019-10-25 艾慕恩治疗公司 坚果粉的制造方法和用于口服免疫疗法的配方
FR3062797B1 (fr) 2017-02-10 2025-03-07 Centre Hospitalier Et Univ De Clermont Ferrand Gelule a liberation gastro-intestinale destinee a etre utilisee dans une methode permettant de desensibiliser et/ou d'induire une tolerance chez un sujet allergique a l'arachide
USD866320S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Box of boxes for dispensing medicine
USD866322S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Medicine folio
US11406563B2 (en) 2018-07-27 2022-08-09 Société des Produits Nestlé S.A. Oral immunotherapy unit dose dispensing systems and methods
USD866321S1 (en) 2018-07-27 2019-11-12 Aimmune Therapeutics, Inc. Box of boxes for dispensing medicine
US12433945B2 (en) * 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
AU2019401576A1 (en) 2018-12-17 2021-06-24 Société des Produits Nestlé S.A. Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
CA3123605A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
JP7536035B2 (ja) 2019-03-22 2024-08-19 ソシエテ・デ・プロデュイ・ネスレ・エス・アー ピーナツに対する経口免疫療法における全身性アレルギー応答リスク評価
WO2020237181A1 (en) 2019-05-23 2020-11-26 Aimmune Therapeutics, Inc. Methods of treating peanut allergy by oral immunotherapy with low-dose maintenance

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014509606A (ja) 2011-03-17 2014-04-21 ケンブリッジ エンタープライズ リミティッド ピーナッツアレルギーの治療
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
WO2019089978A1 (en) 2017-11-02 2019-05-09 Aimmune Therapeutics, Inc. Methods of oral immunotherapy

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Allergy,2014年,Vol.69,pp.834-844
Allergy,2018年,Vol.73,pp.560-568
Annals of Allergy, Asthma & Immunology,2012年,Vol.109, No.5,pp.348-352.e2
THE LANCET,2014年,Vol.383,pp.1297-1304

Also Published As

Publication number Publication date
CA3137295A1 (en) 2020-11-19
EP3965815A4 (en) 2023-05-31
WO2020231843A1 (en) 2020-11-19
US20200368304A1 (en) 2020-11-26
US20230090380A1 (en) 2023-03-23
JP2022532547A (ja) 2022-07-15
CN113966229A (zh) 2022-01-21
AU2020276213A1 (en) 2021-10-28
US11229673B2 (en) 2022-01-25
EP3965815A1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
US20230090380A1 (en) Methods for improving the quality of life of a patient with a peanut allergy
Wasserman et al. Real-world experience with peanut oral immunotherapy: lessons learned from 270 patients
Emslie et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial
JP7498661B2 (ja) 経口免疫療法の方法
JP7536035B2 (ja) ピーナツに対する経口免疫療法における全身性アレルギー応答リスク評価
Fattore et al. A multicenter, randomized, placebo‐controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy
US20190247333A1 (en) Method of reduction in convulsive seizure frequency
Andres et al. Behavioural changes in patients with intellectual disability treated with perampanel
Upton et al. Oral food challenges: Special considerations
Vandervorst et al. Encephalitis associated with the SARS-CoV-2 virus: a case report
WO2020237181A1 (en) Methods of treating peanut allergy by oral immunotherapy with low-dose maintenance
Sammons et al. Ethical issues of clinical trials in children
Kredlow et al. Exploring the boundaries of post-retrieval extinction in healthy and anxious individuals
US20200054738A1 (en) Peanut oral immunotherapy with maintenance dose
Lloyd et al. Endpoints and outcomes after immunotherapy for food allergy: what is meaningful for patients?
Green et al. Phenotypic psychiatric characterization of children with Williams syndrome and response of those with ADHD to methylphenidate treatment
Mboizi et al. Hydroxyurea therapy for neurological and cognitive protection in pediatric sickle cell anemia in Uganda (BRAIN SAFE II): protocol for a single-arm open label trial
Montero et al. Family interventions in schizophrenia: an analysis of non‐adherence
HK40067853A (en) Methods for improving the quality of life of a patient with a peanut allergy
Akiyama et al. Efficacy of perampanel for anti-N-methyl-D-aspartate receptor encephalitis: A case report
Jossan et al. Validation of the use of the ICD-10 diagnostic code for irritable bowel syndrome in the Swedish National Patient Register
JP2020058355A (ja) 疲労に関与する因子及びその利用
Scheffers et al. Health-Related Quality of Life and Fatigue in Children with Pompe Disease
Tronieri et al. Use of pharmacotherapy to improve weight loss in early non-responders to behavioral treatment
Cukor Anxiety in patients with CKD

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220615

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230427

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230427

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240319

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240402

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240701

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240917

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241016

R150 Certificate of patent or registration of utility model

Ref document number: 7574222

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150